|
English
|
正體中文
|
简体中文
|
0
|
|
???header.visitor??? :
51204712
???header.onlineuser??? :
803
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"angevin e"???jsp.browse.items-by-author.description???
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國立成功大學 |
2023 |
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer
|
Camidge, D.R.;Barlesi, F.;Goldman, J.W.;Morgensztern, D.;Heist, R.;Vokes, E.;Spira, A.;Angevin, E.;Su, W.-C.;Hong, D.S.;Strickler, J.H.;Motwani, Motwani M.;Dunbar, M.;Parikh, A.;Noon, E.;Blot, V.;Wu, J.;Kelly, Kelly K. |
| 臺大學術典藏 |
2020-05-25T07:35:22Z |
Phase II results of dovitinib (TKI258) in patients with metastatic renal cell cancer
|
Escudier B; Gr?nwald V; Ravaud A; Ou Y.-C; Castellano D; Chia-Chi Lin; Gschwend J.E; Harzstark A; Beall S; Pirotta N; Squires M; Shi M; Angevin E. |
| 臺大學術典藏 |
2013 |
Phase i study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma
|
Lopez-Martin J.A; Chia-Chi Lin; Gschwend J.E; Harzstark A; Castellano D; Soria J.-C; Sen P; Chang J; Shi M; Kay A; Escudier B.; Angevin E |
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
